Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Date:




The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events like heart attacks and strokes.



Source link

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related